[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-pulmonary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-pulmonary":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,54,80,108,135,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100643856","vasopressor-agents-in-pulmonary-hypertension-crisis-100643856",false,"NCT07667829","Vasopressor Agents in Pulmonary Hypertension Crisis","Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring","Inclusion Criteria:\n\n1. Age \\> 18 years old;\n2. Signed informed consent form;\n3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and\u002For chronic thromboembolic pulmonary hypertension (CTEPH);\n4. Presenting with manifestations of pulmonary hypertensive crisis;\n5. Receiving both diagnosis and treatment in-hospital;\n6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.\n\nExclusion Criteria:\n\n1. At SCAI stage D or stage E ;\n2. Patients who only receive a diagnosis but no treatment in the hospital;\n3. Uncontrolled hyperthyroidism;\n4. Complicated with angle-closure glaucoma;\n5. Hypersensitivity to the study drug;\n6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;\n7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);\n8. Pregnancy;\n9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.","ALL","18 Years",{"count":19,"type":20},75,"ESTIMATED","INTERVENTIONAL",[23],"NA","Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring",[26,27,28],"Pulmonary Arterial Hypertension (PAH)","Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","Hypertension, Pulmonary",[28,30,31,32,33,34,35,36,37,38,39,40],"Cardiovascular Diseases","Vascular Diseases","Dopamine","Norepinephrine","Epinephrine","Haemodynamic Monitoring","Efficacy and Safety","Chronic thromboembolic pulmonary hypertension","Heart Failure","Pulmonary circulation","Pulmonary Arterial Hypertension","NOT_YET_RECRUITING","2026-06-21",{"date":44,"type":45},"2026-06-25","ACTUAL",{"date":47,"type":20},"2026-06",{"date":49,"type":20},"2029-01-31",{"name":51,"class":52},"China National Center for Cardiovascular Diseases","OTHER_GOV",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100599678","deep-learning-detection-of-pulmonary-hypertension-and-low-ejection-fraction-via-digital-stethoscope-and-3-lead-ecg-100599678","NCT07087613","Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG","Deep Learning for Detection of Pulmonary Hypertension and Reduced Left Ventricular Ejection Fraction Using a Combined Digital Stethoscope and Three-lead Electrocardiogram","PH ELEFT 2-0","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Able and willing to provide informed consent\n* Completed a clinical echocardiogram or right heart catheterization within 7 days before or after study procedures\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Patients who are hospitalized\n* Patients undergoing echocardiography with a limited echocardiogram (does not apply to patients undergoing right heart catheterization)",{"count":63,"type":20},3850,"OBSERVATIONAL","This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension (PH) and low left ventricular ejection fraction (EF ≤ 40%). PH is a condition characterized by high blood pressure in the pulmonary arteries, which can lead to heart failure and carries significant risks if undiagnosed. Low EF, which indicates reduced pumping ability of the heart, is also associated with increased risk of severe cardiac events but can remain undetected because patients often have no symptoms or only nonspecific symptoms.\n\nIn this study, adults undergoing clinically indicated echocardiograms or right heart catheterization at outpatient sites will be invited to participate. Participants will complete a single study session lasting about 20 minutes, during which heart sounds and a three-lead ECG will be collected using the Eko CORE 500 device. If participants have had a clinical 12-lead ECG within 30 days of their echocardiogram or right heart catheterization, those data may also be used for analysis. A clinically indicated echocardiogram or right heart catheterization (RHC) performed within seven days before or after the Eko CORE 500 recording will serve as the reference standard to confirm the presence or absence of PH and low EF.\n\nUp to 3,850 participants may be enrolled across multiple sites to ensure that approximately 3,500 complete the study. The data collected will be used to develop and validate artificial intelligence (AI) algorithms that aim to detect PH and identify low EF, potentially enabling earlier and simpler screening for these conditions in clinical practice.",[28,67],"Heart Failure With Reduced Ejection Fraction","RECRUITING","2026-06-16",{"date":71,"type":45},"2026-06-18",{"date":73,"type":45},"2025-06-15",{"date":75,"type":20},"2027-05-31",{"name":77,"class":78},"Eko Devices, Inc.","INDUSTRY",4,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100453081","phase-3-a-study-providing-treatment-access-in-participants-with-pulmonary-hypertension-completing-a-parent-study-and-having-no-other-option-100453081","NCT05179876","A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option","A Prospective, Open-label, Platform Study for Long-term Follow-up of Participants Using Study Intervention in Pulmonary Hypertension Parent Studies","PLATYPUS","Inclusion Criteria:\n\n* Participant must sign an informed consent form (ICF) (or their legally designated representative must sign) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study\n* Participant treated with oral macitentan or selexipag or fixed dose combination (FDC) of macitentan 10 milligrams (mg) and tadalafil 40 mg at the end of a sponsor parent study and: a) the indication of the parent study is included in the intervention-specific appendices (ISA) (pulmonary arterial hypertension \\[PAH\\]; b) participant has completed the parent study; c) no alternative means of access to study intervention (or equivalent approved therapy) have been identified; d) participant may continue to benefit from treatment with the study intervention; e) Participant is at least 18 years old for macitentan\u002Ftadalafil FDC, and at least 2 years old for macitentan or selexipag\n* A female participant of childbearing potential must: a) have a negative urine or serum pregnancy test prior to first intake of study intervention; b) agree to perform monthly urine pregnancy test up to the end of the safety follow-up period; c) If heterosexually active, agree to follow contraceptive methods until 30 days after the last intake of the study intervention. For pediatric female participants: It is the responsibility of the investigator to ensure appropriate counselling, including consultation with a specialist (if needed), to the participant and\u002For parent(s)\u002F legally designated representative (LDR)(s) on the acceptable method of contraception\n\nExclusion Criteria:\n\nGeneral:\n\n* Participants prematurely discontinued from the study intervention in their parent study\n* Female participant being pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study\n* Planned or current treatment with another investigational treatment\n\nMacitentan-specific:\n\n* Known allergies, hypersensitivity, or intolerance to macitentan or its excipients\n* Hemoglobin less than (\\\u003C) 80 grams per liter (g\u002FL)\n* Serum aspartate (AST) and\u002For alanine aminotransferases (ALT) greater than (\\>) 3\\* upper limit of normal (ULN)\n* Known and documented severe hepatic impairment that is, Child-Pugh Class C. For participants with hepatic impairment, Child-Pugh Class (Child-Pugh score) should be fully assessed and documented in the source documents at screening\n\nSelexipag-specific:\n\n* Known allergies, hypersensitivity, or intolerance to selexipag or its excipients\n* Suspected or known pulmonary veno-occlusive disease (PVOD)\n* Uncontrolled thyroid disease\n* Severe coronary heart disease or unstable angina, myocardial infarction within the last 6 months, decompensated cardiac failure (if not under close medical supervision), severe arrhythmia, cerebrovascular events (for example, transient ischemic attack, stroke) within the last 3 months, or congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension (PH)\n* Known and documented severe hepatic impairment that is, Child-Pugh Class C. For participants with hepatic impairment, Child-Pugh Class (Child-Pugh score) should be fully assessed and documented in the source documents at screening\n* Children only: (a) Current suspicion of intussusception or ileus or gastrointestinal obstruction, per the investigator's judgment; (b) hemoglobin or hematocrit \\\u003C75 percent (%) of the lower limit of normal range\n\nMacitentan\u002Ftadalafil FDC-specific:\n\n* Known allergies, hypersensitivity, or intolerance to macitentan or tadalafil or their excipients\n* Hemoglobin \\\u003C80 g\u002FL\n* Serum aspartate (AST) and\u002For alanine aminotransferases (ALT) \\>3\\* ULN range\n* Known and documented severe hepatic impairment that is, Child-Pugh Class C. For participants with hepatic impairment, Child-Pugh Class should be fully assessed and documented in the source documents at screening\n* Severe renal impairment (estimated glomerular filtration rate \\[eGF\\]\u002Fcreatinine clearance \\\u003C30 milliliter per minute \\[mL\u002Fmin\\])","2 Years",{"count":90,"type":20},280,[92],"PHASE3","The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies \\[NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177, and NCT04175600\\]), to continue to benefit from the intervention after closure of the parent study in case they have no alternative means of access to the study intervention. This study will allow assessment of the long-term safety of each study intervention.",[28],[96,97],"Chronic thromboembolic pulmonary hypertension (CTEPH)","pulmonary arterial hypertension (PAH)","2026-06-04",{"date":100,"type":45},"2026-06-05",{"date":102,"type":45},"2022-05-04",{"date":104,"type":20},"2030-09-30",{"name":106,"class":78},"Actelion",45,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":21,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":5},"100629363","phase-2-study-of-tx000045-in-participants-with-pulmonary-hypertension-due-to-interstitial-lung-disease-100629363","NCT07473700","Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease","An Open-Label Study to Assess the Hemodynamic Effect and the Safety of TX000045 After 16 Weeks of Treatment in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease","Inclusion Criteria:\n\n* Confirmed diagnosis of ILD based on imaging: chest computed tomography (CT) performed within the past 12 months with fibrotic lung disease (greater than or equal to (\\>=) 10 percent (%) lung parenchyma with fibrosis) consistent with idiopathic interstitial pneumonia, ILD in association with connective tissue disease, occupational ILD, or chronic hypersensitivity pneumonitis. Chest CTs will be centrally read for eligibility\n* 40% predicted less than or equal to (\\\u003C=) forced vital capacity (FVC) \\\u003C= 80% predicted at screening\n* At least ONE of the following is required to undergo the first screening visit: Documented diagnostic right heart catheterization (RHC) within 18 months of screening with mean pulmonary arterial pressure (mPAP) \\>= 25 millimeters of mercury (mm Hg), pulmonary capillary wedge pressure (PCWP) \\\u003C=15 mm Hg, and pulmonary vascular resistance (PVR) \\>=4 Wood units; Documented echocardiogram (ECHO) within 18 months of screening with right ventricular (RV) (or pulmonary artery) systolic pressure \\>46 mm Hg or tricuspid annular plane systolic excursion (TAPSE)\u002F systolic pulmonary artery pressure (SPAP) \\\u003C=0.38 and absence of clinically significant left ventricular dysfunction as assessed by the investigator\n\nExclusion Criteria:\n\n* Participants have a confirmed or suspected diagnosis of pulmonary hypertension in World Health Organization (WHO) Group 1, WHO Group 2, WHO Group 4, or WHO Group 5\n* Participants have received phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, soluble guanylate cyclase stimulators, intravenous (IV) or subcutaneous (SC) prostacyclin analogues within 30 days before the first screening visit, or sotatercept within 180 days before the first screening visit\n* Participants have any type of pulmonary and cardiovascular comorbidities as defined n protocol\n* Participants who are taking disease-modifying therapy for the underlying interstitial lung disease (ILD) (anti-fibrotics, immunosuppressives, and anti-inflammatory medications) who are not on stable doses for \\>30 days before the first screening visit or have initiated new ILD-directed therapies within 90 days before the first screening visit","80 Years",{"count":117,"type":20},25,[119],"PHASE2","The primary purpose of this study is to assess the effect of TX000045 on pulmonary vascular resistance (PVR) in participants with pulmonary hypertension secondary to interstitial lung disease (PH-ILD) and to assess the safety and tolerability of TX000045 in participants with PH-ILD.",[28,122],"Lung Diseases, Interstitial",[124,125],"Interstitial lung disease","pulmonary vascular resistance","2026-03-10",{"date":128,"type":45},"2026-03-16",{"date":130,"type":20},"2026-03-30",{"date":132,"type":20},"2027-12-11",{"name":134,"class":78},"Tectonic Operating Company, Inc.",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100599061","a-deep-learning-enabled-electrocardiogram-for-detecting-pulmonary-hypertension-100599061","NCT07079592","A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension","A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension: A Randomized Controlled Trial","ADDPH","Inclusion Criteria:\n\n* Men or women, ≥ 50 to 85 years of age\n* At least one 12-lead ECG within 3 months\n\nExclusion Criteria:\n\n* A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5\n* A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy\n* Prior heart, lung, or heart-lung transplants\n* Any systolic pulmonary artery pressure \\>50 mmHg by echocardiography before\n* Echocardiography in 3 months before index ECG","50 Years","85 Years",{"count":146,"type":20},8666,[23],"This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.",[150,151,28],"Artificial Intelligence (AI)","Artificial Intelligence (AI) in Diagnosis",[153,154,155,156],"Artificial intelligence","electrocardiogram","deep learning","pulmonary hypertension","2026-02-23",{"date":159,"type":45},"2026-02-24",{"date":161,"type":20},"2026-02",{"date":163,"type":20},"2026-06-15",{"name":165,"class":166},"National Defense Medical Center, Taiwan","OTHER",1,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":167},"100494533","functional-pulmonary-capillary-surface-area-in-bpa-for-cteph-100494533","NCT05719415","Functional Pulmonary Capillary Surface Area in BPA for CTEPH","Assessment of Recovery of Functional Capillary Surface Area in Patients Undergoing a Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension","Inclusion Criteria:\n\n* All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension\n\nExclusion Criteria:\n\n* Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,\n* Presence of patent foramen ovale","75 Years",{"count":177,"type":20},40,[23],"Chronic thromboembolic pulmonary hypertension \\[CTEPH\\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \\[BPA\\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \\[FCSA\\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.",[28,181],"Pulmonary Thromboembolisms","2025-09-22",{"date":184,"type":45},"2025-09-23",{"date":186,"type":45},"2023-03-23",{"date":188,"type":20},"2028-01-30",{"name":190,"class":166},"Jewish General Hospital"]